Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms

A panel of experts review several updates in myelodysplastic syndromes (MDS) that were presented at ASCO 2023 and other recent meetings and discuss how the data may change treatment approaches in clinical practice.

EP. 1: Diagnosing Myelodysplastic Syndromes (MDS)

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

EP. 2: Risk Stratification of MDS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

EP. 3: First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

EP. 4: Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

EP. 5: Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

EP. 6: Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

EP. 7: Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

July 13th 2023

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

EP. 8: Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

July 13th 2023

Panelists review the presented patient profile and shares how they would have approached treatment.

EP. 9: Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

July 20th 2023

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

EP. 10: Treatment Approaches for Lower-Risk MDS With RAS Mutations

July 20th 2023

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

EP. 11: ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

July 28th 2023

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

EP. 12: Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

July 28th 2023

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

EP. 13: Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

August 3rd 2023

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

EP. 14: Oral HMAs in Lower-Risk MDS Treatment

August 3rd 2023

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

EP. 15: IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

August 10th 2023

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

EP. 16: Key Trials in the Treatment of Higher-Risk MDS

August 10th 2023

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

EP. 17: Final Thoughts on Recent Data Updates in MDS

August 17th 2023

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.